5
|
Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2020; 12:CD004022. [PMID: 33314019 PMCID: PMC8094404 DOI: 10.1002/14651858.cd004022.pub5] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Recent cohort studies show that salt intake below 6 g is associated with increased mortality. These findings have not changed public recommendations to lower salt intake below 6 g, which are based on assumed blood pressure (BP) effects and no side-effects. OBJECTIVES To assess the effects of sodium reduction on BP, and on potential side-effects (hormones and lipids) SEARCH METHODS: The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to April 2018 and a top-up search in March 2020: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. The top-up search articles are recorded under "awaiting assessment." SELECTION CRITERIA Studies randomizing persons to low-sodium and high-sodium diets were included if they evaluated at least one of the outcome parameters (BP, renin, aldosterone, noradrenalin, adrenalin, cholesterol, high-density lipoprotein, low-density lipoprotein and triglyceride,. DATA COLLECTION AND ANALYSIS Two review authors independently collected data, which were analysed with Review Manager 5.3. Certainty of evidence was assessed using GRADE. MAIN RESULTS Since the first review in 2003 the number of included references has increased from 96 to 195 (174 were in white participants). As a previous study found different BP outcomes in black and white study populations, we stratified the BP outcomes by race. The effect of sodium reduction (from 203 to 65 mmol/day) on BP in white participants was as follows: Normal blood pressure: SBP: mean difference (MD) -1.14 mmHg (95% confidence interval (CI): -1.65 to -0.63), 5982 participants, 95 trials; DBP: MD + 0.01 mmHg (95% CI: -0.37 to 0.39), 6276 participants, 96 trials. Hypertension: SBP: MD -5.71 mmHg (95% CI: -6.67 to -4.74), 3998 participants,88 trials; DBP: MD -2.87 mmHg (95% CI: -3.41 to -2.32), 4032 participants, 89 trials (all high-quality evidence). The largest bias contrast across studies was recorded for the detection bias element. A comparison of detection bias low-risk studies versus high/unclear risk studies showed no differences. The effect of sodium reduction (from 195 to 66 mmol/day) on BP in black participants was as follows: Normal blood pressure: SBP: mean difference (MD) -4.02 mmHg (95% CI:-7.37 to -0.68); DBP: MD -2.01 mmHg (95% CI:-4.37, 0.35), 253 participants, 7 trials. Hypertension: SBP: MD -6.64 mmHg (95% CI:-9.00, -4.27); DBP: MD -2.91 mmHg (95% CI:-4.52, -1.30), 398 participants, 8 trials (low-quality evidence). The effect of sodium reduction (from 217 to 103 mmol/day) on BP in Asian participants was as follows: Normal blood pressure: SBP: mean difference (MD) -1.50 mmHg (95% CI: -3.09, 0.10); DBP: MD -1.06 mmHg (95% CI:-2.53 to 0.41), 950 participants, 5 trials. Hypertension: SBP: MD -7.75 mmHg (95% CI:-11.44, -4.07); DBP: MD -2.68 mmHg (95% CI: -4.21 to -1.15), 254 participants, 8 trials (moderate-low-quality evidence). During sodium reduction renin increased 1.56 ng/mL/hour (95%CI:1.39, 1.73) in 2904 participants (82 trials); aldosterone increased 104 pg/mL (95%CI:88.4,119.7) in 2506 participants (66 trials); noradrenalin increased 62.3 pg/mL: (95%CI: 41.9, 82.8) in 878 participants (35 trials); adrenalin increased 7.55 pg/mL (95%CI: 0.85, 14.26) in 331 participants (15 trials); cholesterol increased 5.19 mg/dL (95%CI:2.1, 8.3) in 917 participants (27 trials); triglyceride increased 7.10 mg/dL (95%CI: 3.1,11.1) in 712 participants (20 trials); LDL tended to increase 2.46 mg/dl (95%CI: -1, 5.9) in 696 participants (18 trials); HDL was unchanged -0.3 mg/dl (95%CI: -1.66,1.05) in 738 participants (20 trials) (All high-quality evidence except the evidence for adrenalin). AUTHORS' CONCLUSIONS In white participants, sodium reduction in accordance with the public recommendations resulted in mean arterial pressure (MAP) decrease of about 0.4 mmHg in participants with normal blood pressure and a MAP decrease of about 4 mmHg in participants with hypertension. Weak evidence indicated that these effects may be a little greater in black and Asian participants. The effects of sodium reduction on potential side effects (hormones and lipids) were more consistent than the effect on BP, especially in people with normal BP.
Collapse
Affiliation(s)
- Niels Albert Graudal
- Department of Rheumatology VRR4242, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | | | - Gesche Jurgens
- Clinical Pharmacology Unit, Roskilde Hospital, Roskilde, Denmark
| |
Collapse
|
7
|
Birukov A, Andersen LB, Herse F, Rakova N, Kitlen G, Kyhl HB, Golic M, Haase N, Kräker K, Müller DN, Jørgensen JS, Andersen MS, Dechend R, Jensen BL. Aldosterone, Salt, and Potassium Intakes as Predictors of Pregnancy Outcome, Including Preeclampsia. Hypertension 2019; 74:391-398. [PMID: 31177907 DOI: 10.1161/hypertensionaha.119.12924] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The mineralocorticoid aldosterone increases in plasma in healthy pregnancy along with renin and angiotensin II and plays a key role in the physiological plasma volume expansion. In mice, aldosterone contributes to an optimal fetal development by enhancing PlGF (placental growth factor) expression and trophoblast cell proliferation. In preeclampsia, there is coincident suppression of aldosterone and impaired placental development. We hypothesized that aldosterone independently contributes to placental and birth weight in humans, and high dietary sodium and low potassium intakes affect this relationship adversely. We analyzed 24-hour urine collections and plasma samples from gestational week 29 in a subsample of 569 pregnant women from the Odense Child Cohort-a Danish population-based longitudinal cohort study. Plasma and urinary aldosterone were measured by ELISA, sodium and potassium excretions by flame photometer. Predictive values of aldosterone levels and sodium and potassium intakes were assessed by multiple and Cox regression analyses. Primary outcomes were placental weight and birth weight. Secondary outcome was preeclampsia. Urinary aldosterone excretion at gestational week 29 independently contributed to placental and birth weights (adjusted β-coefficients [95% CI], 24.50 [9.66-39.35] and 9.59 [4.57-14.61], respectively). Aldosterone levels were not associated to preeclampsia incidence. Salt intake >6 g/d was associated with development of preeclampsia (hazard ratio [95% CI], 5.68 [1.51-21.36]). At gestational week 29, urinary aldosterone excretion is an independent predictor of placental and birth weights. High salt intake is a risk factor for preeclampsia. In perspective, suppression of aldosterone in pregnancy has adverse trophic effects.
Collapse
Affiliation(s)
- Anna Birukov
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,German Centre for Cardiovascular Research, Partner Site Berlin, Germany (A.B., M.G., N.H., K.K., D.N.M., R.D.).,Department of Obstetrics and Gynecology (A.B., L.B.A., J.S.J., R.D.), Odense University Hospital, Denmark
| | - Louise Bjørkholt Andersen
- Institute of Clinical Research (L.B.A., J.S.J.), University of Southern Denmark, Odense.,Department of Obstetrics and Gynecology, Herlev Hospital, Denmark (L.B.A.).,Department of Obstetrics and Gynecology (A.B., L.B.A., J.S.J., R.D.), Odense University Hospital, Denmark
| | - Florian Herse
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.)
| | - Natalia Rakova
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.)
| | - Gitte Kitlen
- Institute for Molecular Medicine (G.K., B.L.J.), University of Southern Denmark, Odense
| | - Henriette Boye Kyhl
- Odense Child Cohort, Hans Christian Andersen Hospital for Children and Adolescents (H.B.K., J.S.J.), Odense University Hospital, Denmark.,Odense Patient Data Explorative Network (H.B.K., J.S.J.), Odense University Hospital, Denmark
| | - Michaela Golic
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,German Centre for Cardiovascular Research, Partner Site Berlin, Germany (A.B., M.G., N.H., K.K., D.N.M., R.D.)
| | - Nadine Haase
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,German Centre for Cardiovascular Research, Partner Site Berlin, Germany (A.B., M.G., N.H., K.K., D.N.M., R.D.)
| | - Kristin Kräker
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,German Centre for Cardiovascular Research, Partner Site Berlin, Germany (A.B., M.G., N.H., K.K., D.N.M., R.D.)
| | - Dominik N Müller
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,German Centre for Cardiovascular Research, Partner Site Berlin, Germany (A.B., M.G., N.H., K.K., D.N.M., R.D.)
| | - Jan Stener Jørgensen
- Institute of Clinical Research (L.B.A., J.S.J.), University of Southern Denmark, Odense.,Odense Child Cohort, Hans Christian Andersen Hospital for Children and Adolescents (H.B.K., J.S.J.), Odense University Hospital, Denmark.,Odense Patient Data Explorative Network (H.B.K., J.S.J.), Odense University Hospital, Denmark.,Department of Obstetrics and Gynecology (A.B., L.B.A., J.S.J., R.D.), Odense University Hospital, Denmark
| | | | - Ralf Dechend
- From the Experimental and Clinical Research Center, a joint cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,Charité-Universitätsmedizin Berlin (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.), corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.B., F.H., N.R., M.G., N.H., K.K., D.N.M., R.D.).,German Centre for Cardiovascular Research, Partner Site Berlin, Germany (A.B., M.G., N.H., K.K., D.N.M., R.D.).,Department of Obstetrics and Gynecology (A.B., L.B.A., J.S.J., R.D.), Odense University Hospital, Denmark.,Department of Cardiology and Nephrology, HELIOS-Klinikum, Berlin, Germany (R.D.)
| | - Boye L Jensen
- Institute for Molecular Medicine (G.K., B.L.J.), University of Southern Denmark, Odense
| |
Collapse
|